Daiichi Sankyo
Daiichi Sankyo K. K. (Japanese第一 三 共 株式会社, Daiichi Sankyo Kabushiki - gaisha, Eng. Daiichi Sankyo Co., Ltd.. ) is a common Japanese holding company, on 28 September 2005 by the two Japanese pharmaceutical company Sankyo KK (三 共 株式会社, Eng. Sankyo Co., Ltd.). Daiichi Seiyaku KK and (第一 制 薬 株式会社. Daiichi Seiyaku Kabushiki - gaisha, Eng. Daiichi Pharmaceutical Co., Ltd.) was established. She's in the Nikkei 225 listed under ISIN JP3475350009.
Daiichi Sankyo is a global, research-based pharmaceutical companies. The corporate headquarters is located in Tokyo. Founded in 1899, Daiichi Sankyo has been working since the beginning of the industrial manufacture of medicines in the research, development and production of innovative drugs.
The European roots of the Group date back to the year 1910. Currently, the company is represented in twelve European countries; these include with Germany, Great Britain, France, Italy and Spain, the major European pharmaceutical markets.
Daiichi Sankyo employs nearly 30,000 employees (2010) and generated net sales of € 7.26 billion ( € 757 million in Europe ) in the 2009 financial year. In fiscal 2009, 1.55 billion euros were invested in research and development, representing 20.7 percent of net turnover. In its research activities, the company focuses on the areas of cardiovascular disease, diabetes and metabolic disorders, infectious diseases and cancers.
Ranbaxy Laboratories, India's largest pharmaceutical company, in November 2008, part of the group was. In the leading pharmaceutical companies in the world ranking Daichi Sankyo is among the top 20 belongs in Japan Daichi Sankyo to the top 3 pharmaceutical companies.
The company is headquartered in Chūō, Tokyo. The European headquarters, Daiichi Sankyo Europe GmbH and its German subsidiary, Daiichi Sankyo Germany GmbH, located in Munich, respectively. In Europe, Daiichi Sankyo currently has 12 country offices and employs over 2,500 employees, including nearly 1,500 in the field.
The olmesartan family of molecules represents represents the most effective substances / products
In cooperation with licensees drugs are sold in more than 60 countries around the globe.
In July 2008, Merck Pharma GmbH, a 100 % subsidiary of Merck KGaA of Darmstadt, Germany announced that Daiichi Sankyo will assume as part of an expansion in the German pharmaceutical market 130 field staff under the existing conditions.
In early March, 2011, the Japanese parent company announced that it will take over the Plexxikon Inc. for approximately 800 million U.S. dollars. Plexxikon Inc. is a Berkeley, California and geographically pharmaceutical company that specializes in the development of oncology drugs. The frontrunner is vemurafenib, previously developed in collaboration with Roche for the treatment of metastatic skin cancer.
The best-known drugs of Daiichi Sankyo Group
- Effient ( prasugrel )
- Olmetec ( olmesartan )
- Olmetec Plus ( olmesartan and hydrochlorothiazide )
- Evista ( Raloxifene )
- Sevikar ( olmesartan and amlodipine)
- Sevikar HCT ( olmesartan medoxomil, amlodipine and hydrochlorothiazide)
- Orelox ( cefpodoxime proxetil )
- Combizym ( Aspergillus-oryzae-Enzymgemisch/Pankreas-Pulver )
- Mevalotin ( pravastatin )
- Loxonin ( Loxoprofen )
- Captopril
- Zantac ( ranitidine )
- WelChol ( colesevelam )
- Cravit ( levofloxacin )
- Evoxac ( cevimeline )
- FloxinOtic (Ofloxacin )
- Loporesor (Metoprolol )
- Lomir / ICAZ ( isradipine )
- Luivac
- Benicar ( Olmesartan )
- Mobilat ( chondroitin, salicylic acid), one of the best known medicine for pain in the muscles and joints, was sold to the German generics manufacturer STADA 2005.
- Lixiana ( Edoxaban )